Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 132

Similar articles for PubMed (Select 23246550)

1.

Cost-effectiveness of childhood influenza vaccination in England and Wales: Results from a dynamic transmission model.

Pitman RJ, Nagy LD, Sculpher MJ.

Vaccine. 2013 Jan 30;31(6):927-42. doi: 10.1016/j.vaccine.2012.12.010. Epub 2012 Dec 14.

2.

Estimating the clinical impact of introducing paediatric influenza vaccination in England and Wales.

Pitman RJ, White LJ, Sculpher M.

Vaccine. 2012 Feb 1;30(6):1208-24. doi: 10.1016/j.vaccine.2011.11.106. Epub 2011 Dec 13.

3.

Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.

Lugnér AK, van Boven M, de Vries R, Postma MJ, Wallinga J.

BMJ. 2012 Jul 12;345:e4445. doi: 10.1136/bmj.e4445.

4.

Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States.

Prosser LA, Lavelle TA, Fiore AE, Bridges CB, Reed C, Jain S, Dunham KM, Meltzer MI.

PLoS One. 2011;6(7):e22308. doi: 10.1371/journal.pone.0022308. Epub 2011 Jul 29.

5.

Health and economic impact of the seasonal influenza vaccination programme in England.

Baguelin M, Jit M, Miller E, Edmunds WJ.

Vaccine. 2012 May 14;30(23):3459-62. doi: 10.1016/j.vaccine.2012.03.019. Epub 2012 Mar 22.

PMID:
22446636
6.

The cost-effectiveness of vaccinating pregnant women against seasonal influenza in England and Wales.

Jit M, Cromer D, Baguelin M, Stowe J, Andrews N, Miller E.

Vaccine. 2010 Dec 10;29(1):115-22. doi: 10.1016/j.vaccine.2010.08.078. Epub 2010 Nov 4.

PMID:
21055501
7.

Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada.

Fisman DN, Tuite AR.

PLoS One. 2011;6(11):e27420. doi: 10.1371/journal.pone.0027420. Epub 2011 Nov 14.

8.

The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.

Aballéa S, De Juanes JR, Barbieri M, Martin M, Chancellor J, Oyagüez I, Verwee B, Largeron N.

Vaccine. 2007 Sep 28;25(39-40):6900-10. Epub 2007 Aug 6.

PMID:
17764790
9.

The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.

Aballéa S, Chancellor J, Martin M, Wutzler P, Carrat F, Gasparini R, Toniolo-Neto J, Drummond M, Weinstein M.

Value Health. 2007 Mar-Apr;10(2):98-116.

PMID:
17391419
10.

Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation.

Baguelin M, Hoek AJ, Jit M, Flasche S, White PJ, Edmunds WJ.

Vaccine. 2010 Mar 11;28(12):2370-84. doi: 10.1016/j.vaccine.2010.01.002. Epub 2010 Jan 21.

PMID:
20096762
11.

Cost-effectiveness of influenza vaccination in working-age cancer patients.

Avritscher EB, Cooksley CD, Geraci JM, Bekele BN, Cantor SB, Rolston KV, Elting LS.

Cancer. 2007 Jun 1;109(11):2357-64.

12.

Cost effectiveness analysis of elementary school-located vaccination against influenza--results from a randomized controlled trial.

Yoo BK, Humiston SG, Szilagyi PG, Schaffer SJ, Long C, Kolasa M.

Vaccine. 2013 Apr 19;31(17):2156-64. doi: 10.1016/j.vaccine.2013.02.052. Epub 2013 Mar 13.

PMID:
23499607
13.

Public health and economic benefits of new pediatric influenza vaccination programs in Argentina.

Giglio N, Gentile A, Lees L, Micone P, Armoni J, Reygrobellet C, Crépey P.

Hum Vaccin Immunother. 2012 Mar;8(3):312-22. doi: 10.4161/hv.18569. Epub 2012 Feb 14.

14.

Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.

Clements KM, Chancellor J, Nichol K, DeLong K, Thompson D.

Value Health. 2011 Sep-Oct;14(6):800-11. doi: 10.1016/j.jval.2011.03.005.

PMID:
21914499
15.

Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age.

Allsup S, Gosney M, Haycox A, Regan M.

Health Technol Assess. 2003;7(24):iii-x, 1-65.

16.

Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.

Brydak L, Roiz J, Faivre P, Reygrobellet C.

Clin Drug Investig. 2012 Feb 1;32(2):73-85. doi: 10.2165/11594030-000000000-00000.

PMID:
22201294
17.

The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia.

Newall AT, Scuffham PA, Kelly H, Harsley S, Macintyre CR.

Vaccine. 2008 Apr 16;26(17):2142-53. doi: 10.1016/j.vaccine.2008.01.050. Epub 2008 Feb 20.

PMID:
18343537
18.

Estimating the impact of childhood influenza vaccination programmes in England and Wales.

Vynnycky E, Pitman R, Siddiqui R, Gay N, Edmunds WJ.

Vaccine. 2008 Sep 26;26(41):5321-30. doi: 10.1016/j.vaccine.2008.06.101. Epub 2008 Jul 21.

PMID:
18647634
19.

Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.

Melegaro A, Edmunds WJ.

Vaccine. 2004 Oct 22;22(31-32):4203-14.

PMID:
15474710
20.

Cost-effectiveness of influenza vaccination of healthy children.

Salo H, Kilpi T, Sintonen H, Linna M, Peltola V, Heikkinen T.

Vaccine. 2006 Jun 5;24(23):4934-41. Epub 2006 Apr 7.

PMID:
16678945
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk